Market Place
Sourcing Support
FDA Accepts BLA for HLX14, Biosimilar Candidate of PROLIA/XGEVA
30 Oct 2024 //
BUSINESSWIRE
Primary Endpoint Met In Ph 3 Study Of Perjeta Biosimilar HLX11
30 Sep 2024 //
PRESS RELEASE
EMA validates Henlius & Organon’s Mkg authorization for Prolia& Xgeva biosimilar
27 May 2024 //
PHARMIWEB
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius
25 Oct 2023 //
PR NEWSWIRE
Henlius` Novel Anti-PD-1 mAb HANSIZHUANG Approved for the Treatment of ESCC
22 Sep 2023 //
PRESS RELEASE
Henlius to Release the Preclinical Profiles of 2 ADC Programs at ESMO Congress
21 Sep 2023 //
PRESS RELEASE
Phase 3 Study Results of a Novel Anti-PD-1 mAb HANSIZHUANG Released at WCLC 2023
11 Sep 2023 //
PRESS RELEASE
Shanghai Henlius secures AEMPS approval for breast cancer therapy trial
31 Oct 2022 //
CLINICALTRIALSARENA
ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA
28 Sep 2022 //
PRNEWSWIRE
Henlius’ Pertuzumab Biosimilar Shows Similar PK Profile to Reference Product
02 Jul 2022 //
CENTERFORBIOSIMILARS
Henlius Released PIII Study Results for 1L-SCLC of Serplulimab at ASCO 2022
06 Jun 2022 //
PRNEWSWIRE
Henlius` Serplulimab Granted ODD in U.S. for SCLC
07 Apr 2022 //
PRNEWSWIRE
NMPA Approves Henlius` First Innovative MAb HANSIZHUANG
25 Mar 2022 //
PRNEWSWIRE
Henlius` anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line of SCLC
20 Dec 2021 //
PRNEWSWIRE
Henlius` Phase 3 study of serplulimab for ES-SCLC meets primary endpoint
07 Dec 2021 //
PRNEWSWIRE
Eurofarma brings three biosimilars to Latin America that will expand access to cancer treatment
11 May 2021 //
PRESS RELEASE
The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA
22 Apr 2021 //
BIOSPACE
Mr. Wenjie Zhang appointed as the CEO of Henlius to keep innovating
30 Sep 2020 //
PRESS RELEASE
Henlius granted exclusive development and commercialisation rights of HLX02
30 Sep 2020 //
PRESS RELEASE
Henlius Bevacizumab Biosimilar Received NDA Acceptance Notification from NMPA
10 Sep 2020 //
FIRSTWORD PHARMA
Shanghai Henlius Biotech’s trastuzumab biosimilar HLX02 gets China NMPA approval
18 Aug 2020 //
PHARMABIZ
Henlius Biotech Gets NMPA Nod for Denosumab Biosimilar
25 Jun 2020 //
CENTERFORBIOSIMILARS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.